ClinicalTrials.gov
public full text
Public Domain
Cilengitide in Treating Children With Refractory Primary Brain Tumors
This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma#1245956
- Cilengitide in Treating Patients With Acute Myeloid Leukemia#1308742
- Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy#849967
- Cilengitide Imaging Trial in Glioblastoma#1125681
- Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma#842840
Record · ID 1431130
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive